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Tuberculosis (TB) is an important cause of morbidity and mortality in children.1 2 The incidence 
and severity of childhood TB is increased by HIV infection.3 HIV-infected children with TB 
infection are at risk of more rapid progression to disease, more severe disease and increased 
mortality.4-6 The Western Cape in South Africa has an extremely high incidence of TB especially 
among HIV-infected infants.3 
There are relatively few interventions to decrease the risk of childhood TB in HIV-
infected children. Adult studies have shown that INH preventative therapy (IPT) decreases the 
risk TB in HIV-infected adults on ART.7 8 There are currently no such studies in children 
although it has been shown that IPT and ART independently decrease the risk of tuberculosis in 
children.9-12 
The aim of this study is to investigate the combined effect of IPT and ART on TB 
incidence in HIV-infected children. A cohort analysis will be performed using data from a 
prospective, double-blinded placebo controlled trial of INH versus placebo in HIV-infected 
children in Cape Town, South Africa.9 Ethical approval for this study was obtained from the 
Research and Ethics committees of Faculty of Health Sciences of the Universities of Cape 














In Cape Town, South Africa, the incidence of TB in children has been reported to be 
approximately 407/100 000 population and to account for around 13.7% of the total TB 
burden.13 This burden of TB was 20 times higher among HIV-infected than uninfected children - 
with 23 active cases of TB seen per 100 HIV-infected children compared to 7.2 in HIV 
uninfected.14 
HIV-infected children are at increased risk of developing TB due to a higher burden of 
exposure to TB infected cases and impaired immunity.15 HIV-infected children with severe 
immuno-suppression (CD4 percentage < 15% and viral load > 100 000) are at a 4 times 
increased risk (12.4% versus 3.3 % in children with a CD4 count greater or equal to 15%) of 
progression to TB disease over 3 years.16  
Bacille Callmette Guerin (BCG) vaccination, IPT and ART are possible strategies to 
prevent TB in HIV–infected children. World Health Organization (WHO) guidelines have recently 
been revised to advise against BCG vaccination in HIV-infect d infants due to the high risk of 
disseminated BCG and associated mortality.17 
IPT is part of standard guidelines to prevent TB in HIV-infected and uninfected children 
who have household exposure to adult TB. Adult studies have shown that IPT decreases TB 
incidence in HIV-infected adults with a positive tuberculin skin test (TST), however there are few 
studies in children. IPT is rarely rolled out in resource limited countries where access to 
screening tools for TB is limited.18 It is important to accurately exclude TB disease before 
starting IPT otherwise there is the risk of using mono-therapy and the possibility of drug 
resistant TB developing. 
The use of ART has also been shown to decrease the incidence of TB in children. The 
incidence of TB in children on ART versus those not on ART is 6.4 cases per 100 patient years 
versus 53.3 cases /100 patient years (OR 16.6- 95% CI 12.5-22.4).10 Studies in Brazil and 
South Africa have shown that ART reduces the incidence of TB by around 70 to 80%.8 19 
However, the risk of TB still remains higher than that in HIV-uninfected children. 
Observational studies suggest that INH preventive therapy is protective in adults receiving 
ART.8 19 Several randomized trials investigating the combined effect of INH prophylaxis and 
ART are underway in adults but data in children are scarce. The objective of this study will be to 
investigate the combined effect of INH prophylaxis and ART on TB incidence in HIV-infected 



















Retrospective analysis of data that was obtained in a prospective cohort study will be carried out 
to investigate the effect of INH and ART on TB incidence. Individuals will be censored at death, 
date of TB diagnosis, loss to follow up or on 31 December 2007 (the time at which INH 
prophylaxis was discontinued in the study cohort). Individuals may contribute time to four 
groups: time on placebo, time on INH only, time on ART only, time on ART and INH. 
Confounding variables to be investigated include 
• (At enrolment) 
• Nutritional status 




• Prior TB 
 
Study Site 
The original study was done at Red Cross War Memorial Children’s Hospital and Tygerberg 
Children’s Hospital, both situated in Cape Town, South Africa. 
 
Study Population 
The study population comprised HIV-infected children older than 8 weeks attending Red Cross 
















• Ability to attend regular follow-up visits 
 
Exclusion criteria 
• Current use or need for INH prophylaxis 
• Prior hypersensitivity to sulphur drugs or INH 
• Severe anaemia (haemoglobin < 70 g /l) 
• Neutropaenia (absolute neutrophil count < 400 cells /ul)  
• Non-reversible renal failure 
 
TB disease at the time of enrolment was not an exclusion criterion. Children completed TB 
therapy according to national guidelines and thereafter were randomized to INH or placebo.  
 
Follow-up 
As part of the original study children were evaluated every four weeks for the first six months, 
every six weeks for the second six months and thereafter every two to three months depending 
on medical and social circumstances. Clinical and historical data were collected at each visit. A 
tuberculin skin test (TST, 2 TU RT23, Staten Serum Institute, Copenhagen, Denmark), and 
chest radiograph (CXR) were done at 6 monthly intervals. A child exposed to a TB source 
(case), hospitalized for respiratory illness, or developing symptoms of TB at any time during the 
study period was investigated for TB infection and disease. For pulmonary TB this included a 
TST, a chest radiograph and two induced sputum specimens for acid fast staining and 
Mycobacterium tuberculosis (M. tuberculosis) culture. Additional specimens were submitted as 
clinically indicated. Children exposed to a household TB case were given INH prophylaxis 




Enrolment began in January 2003. Children enrolled before May 2004 were randomly allocated 
to receive INH (10 mg/kg) or placebo. All children receiving placebo were switched to INH 
prophylaxis in May 2004 on the advice of the Data Safety and Monitoring Board (DSMB) due to 
the decreased mortality observed in children on INH.9 All children enrolled thereafter received 
INH. INH was stopped in all children in December 2007 on the advice of the DSMB as most 














ART was not widely available at the start of the study but was obtained for some children 
through the participation in pharmaceutical trials or charitable donations. Standard guidelines for 
ART in children were developed after the establishment of the national ART programme in 
2004. Thereafter increasing numbers of children initiated therapy according to medical and 
social criteria described in the national guidelines.  
 
Diagnosis of TB 
Cases of TB were classified as definite or probable according to clinical, radiological and 
microbiological findings as follows:  
Definite TB: culture positive for M tuberculosis on a sputum or other sample 
Probable TB: CXR suggestive of TB (lymphadenopathy, miliary pattern, pleural effusion, 
bronchial compression or parenchymal infiltrate) plus at least one of the following: a positive 
TST, a history of a close contact with an adult with TB, loss of weight or failure to gain weight 
within the previous 3 months, or a positive smear microscopy for acid fast bacilli on sputum.  
Chest radiographs were reported by a single radiologist, blinded to the diagnosis of TB, 
according to a standardized format. Probable cases were reviewed by an independent 





All data being used in the cohort analysis will be extracted from pre-existing databases. 
 
Proposed analysis 
The analysis will be conducted using Stata (version 10.1, College Station, Texas) Descriptive 
statistics of the baseline data and follow-up data of the cohort will be calculated as medians, 
25th and 75th percentiles and frequencies. 
Cox proportional hazards regression will be performed using time since randomization as the 
time scale. A univariate analysis will be  conducted using immunodeficiency, anthropometric z-
scores and age at enrolment, gender, prior TB, cotrimoxazole daily or three times per week, 












Age and immunodeficiency at enrolment will be included a priori in the multivariate model. 
Possible other confounders including WHO clinical staging and nutritional status at enrolment 
and prior TB, gender and cotrimoxazole will be assessed with regards to their impact on the 





Strict confidentiality was maintained at all times.  No identifying data will be included in the 
database so participants will remain anonymous.   
 
Informed Consent 




Ethical approval (Rec: 057/2002) was obtained from the research and ethics committees of the 
Faculty of Health Sciences (FHS) of Universities of Cape Town and Stellenbosch, South Africa 
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PART B: LITERATURE REVIEW 
Background 
 
Globally, HIV and TB are dual epidemics that affect children, especially those living in Sub- 
Saharan Africa. HIV-infected children with TB infection are at risk of more rapid progression 
to TB disease, more severe TB disease and increased mortality compared to HIV-
uninfected children.1-4 Conversely, TB increases HIV viral replication and progression to 
AIDS. 5  
 
Diagnostic difficulties and poor reporting systems have made it difficult to accurately 
quantify the global burden of childhood TB.6 A community based South African study 
showed that children less than 13 years of age contributed approximately 13.7% of the total 
TB disease burden with a calculated incidence of 408/100 000.7 In children under 2 years, 
this incidence was even higher, approximately 600/100 000.8  
 
Prevention of TB in children is an important goal. The rationale for preventative therapy is 
based on the principle that mycobacterial infection occurs in two stages: infection and 
progression to disease. Children infected with TB have a much higher risk of progression to 
TB disease compared to adults. The TB bacillus can remain dormant for years but children 
are at highest risk of progression to disease within the first two years after infection.9 The 
risk of TB disease in HIV negative infants is 40-50% within the first year after M. 
tuberculosis infection. This risk decreases to 25%, less than 10% and 2% in children 1-2, 2-
5 and more than 5 years of age.10 This high risk of disease in children exposed to TB 
provides the rationale for the international recommendations to make INH Preventative 
Therapy (IPT) available to children under 5 years with a household with TB contact.11 12 
 
Data from immune-competent people has shown that IPT is effective for preventing 
progression from TB infection to disease. A Cochrane review investigated the effect of 6 to 
12 month courses of IPT in HIV negative adults and children with TB exposure.13 Eleven 
trials involving 73,375 patients were included. IPT decreased the risk of developing TB by 
60% (95% CI 0.31-0.52). IPT reduced TB deaths (although this was not statistically 
significant) but not all cause mortality. The effect of IPT lasted at least 2 years following 












effect of IPT. Less than 1% of individuals developed hepatotoxicity while receiving IPT. 
However, only 6 studies included children. Effect estimates presented in the review were 
not stratified by age and thus the magnitude of the effect of IPT in children is unclear. Of 
the six paediatric trials included Comstock reported a risk reduction of 67% in children less 
than 14 years14 and Ferebee and Mount of 50% in children less than 1 year.15  
 
IPT in children was shown to work in other large trials some of which were not included in 
the Cochrane review as they were not randomized. Hsu conducted a prospective study 
spanning 30 years and enrolling 1882 children in the USA.16 17 Children were given INH for 
12-18 months and observed for a mean follow up time of 6 years. In contrast to previous 
natural history data, no child infected before 4 years of age developed disease.16 17 This 
study and other large United States Public Health service trials formed the basis of the 
recommendations for the provision of IPT to all children less than 5 years of age when 
exposed to a TB contact.18 
 
Children in high HIV and TB prevalence settings experience TB exposure at a young age 
because TB is common in HIV-infected women of childbearing age. A South African study 
from KwaZulu Natal showed that TB incidence in HIV -infected women at the time of 
delivery was increased tenfold compared to HIV negative women.19 A study from India 
found that 3.5% of HIV-infected women that had recently given birth developed TB, with the 
median time to development of active TB disease being 3 months postpartum.20 This study 
also described a much higher probability of death in infants whose mothers developed TB 
compared with infants whose mothers did not have TB.20  
 
HIV-infected infants who have failed a Prevention of Mother to Child Transmission  
(PMTCT) program or who have not had access to PMTCT are at increased risk of 
progressing to TB disease after infection with M. tuberculosis.4 A South African study 
reported that HIV-infected infants have a 20-fold higher risk of developing culture confirmed 
tuberculosis disease compared with HIV-uninfected infants.21 
 
The large burden of TB in HIV-infected children can be prevented if available, effective 
strategies are implemented. The choice of prevention strategy depends on TB prevalence, 












In HIV-infected children strategies such as Bacille Callmette-Guerin (BCG) vaccination, 
isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) have been employed to 
prevent TB disease. World Health Organization (WHO) guidelines have recently been 
revised to recommend against BCG vaccination in HIV-infected infants due to the high risk 
of disseminated BCG and associated mortality.22 IPT and ART prevent TB disease through 
different mechanisms but may be used in combination to reduce TB. Adult data has shown 
that IPT significantly decreased the risk of TB in HIV-infected adults taking ART in a high 
incidence operational setting, 23 24 but there is little information on the efficacy of IPT and 















The aim of the review was to assess the evidence for IPT and ART as strategies to 




A literature search for publications on TB prevention in HIV-infected children was performed 
using the terms “HIV infection”, “tuberculosis”, “isoniazid preventive therapy”, “IPT”, 
“Antiretroviral therapy”, “HIV”, “AIDS”, “control” , “prevention”, “children”, “infants” and 
“paediatrics” . Medline and EmBase were searched for published studies from 1990 until 
December 2010. The International AIDS society website and the International Union 
Against Tuberculosis and Lung Disease website were searched for abstracts. The World 
Health Organization (WHO) site was searched for guidelines and publications on TB 
prophylaxis in HIV-infected children. Reference lists of identified primary studies, reviews 
and editorials were scanned. Studies that reported on mycobacteria other than tuberculosis 















INH Preventative Therapy 
 
Data in HIV-infected adults have shown IPT is effective for preventing TB in individuals not 
receiving ART.25 A recent Cochrane review including 12 randomized placebo controlled 
trials with a total of 8578 participants showed that IPT decreased the incidence of active TB 
in HIV-infected adults by 32% (RR 0.68, 95% CI 0.54 to 0.85).25 All regimens regardless of 
drug type, frequency or duration of treatment showed similar efficacy however, multi-drug 
regimens were more likely to be discontinued due to adverse events than INH mono-
therapy. The protective effect of preventive therapy was more pronounced in individuals 
with a positive tuberculin skin test. Chemoprophylaxis did not reduce all cause mortality 
(RR 0.94, 95%CI 0.85 to 1.05). 
 
Paediatric Studies  
One systematic review26 and two randomized controlled trials were found.27 28 
A Cochrane review investigating the impact of IPT on TB disease and death in HIV-infected 
children found only one randomized controlled trial.26 The study  included in the Cochrane 
review was conducted in Cape Town which has one of the highest incidence rates of 
childhood TB in the world 7 . This study b  Zar et al reported a 72% (HR 0.28, 95%CI 0.10 
to 0.77) reduction in TB risk and a 54% (HR 0.46, 95% CI 0.22 to 0.94) decrease of all 
cause mortality in HIV-infected children receiving IPT.27 Most children were severely 
immune compromised and very few were on ART at the time of the study.27 
 
In contrast, results from the P1041 trial conducted in a similar setting in South Africa 
showed no effect of IPT on the risk of TB disease or all cause mortality. 28 The different 
results might be partly explained by differences in study populations (table 1). All children 
enrolled in the P1041 trial were infants (median age 3.3 months) and received ART at the 
time of enrolment, while the median age of children in the Zar study was 29 months and 
only 8% were on ART at enrolment. Children in P1041 were also less immune 
compromised compared to those enrolled in the Zar study. None of the children in the 
P1041 trial had TB disease before enrolment, while 16% of children had been treated for 













Incidence of side effects and adverse events was low in both studies. Zar et al reported 
grade 3 or 4 toxicity (as measured by a 10 fold increase in ALT from baseline) in five 
children (3%) receiving IPT and 8 children (6.1%) receiving placebo.27 No neurological or 
cutaneous toxicity was observed. A study investigating toxicity associated with IPT in HIV- 
infected children on ART reported no episodes of acute liver failure and jaundice and a 
prevalence of grade 3 or 4 liver toxicity of 3.4%.29 Safety data may also be extrapolated 
from larger adult trials. A study of 24221adult HIV-infected mineworkers receiving IPT 
reported adverse events in only 0.54% of the cohort.30  
 
Adherence to IPT in children enrolled on Zar study was reported as excellent with most 




ART is a well established strategy to decrease the incidence of TB disease in HIV-infected 
adults.32 A meta-analysis of nine observational cohort studies enrolling 37879 adult patients 
showed that use of ART was associated with a 67% (95% CI 61-73%; range, 54-92%) 
reduction in TB incidence.33 
 
Data are limited in children. Besides age, immune status is the most important determinant 
of a child’s risk of TB disease. A study from Cote d’Ivoire showed that the risk of TB was 
four times greater in children with a CD4% less than 15% than in those children with a 
CD4% of more than 15%.34 In vitro studies have shown that HIV-infected children have an 
impaired ability to control mycobacterial growth compared with immune competent 
children.35 Initiation of ART leads to a rapid and sustained reconstitution of specific anti-
mycobacterial immune responses.36 By improving immunity ART results in more effective 
containment of TB infection.36 37  
 
Paediatric Studies  
190 articles were identified and these abstracts were read. 12 were reviewed in full text. 
Five studies were not suitable: 2 reported on non tuberculous mycobacteria, 2 did not 
include children, 1 did not report on the impact of ART on TB risk. A total of 7 publications 












high TB incidence; one study was from Jamaica with a TB incidence of 6.6 per 100,000 
population.38 
 
Of the seven studies, 3 did not indicate how the diagnosis of TB was made.39 40 Two studies 
from the Democratic Republic of Congo (DRC) and Kenya had no access to sputum culture 
so used clinical scoring systems for TB diagnosis.41 42 The study from the DRC had no 
access to HIV PCR for confirmation of HIV status in children under 18 months.  
 
Most of the studies included older children between ages 12 months and 16 years, with the 
median age ranging from 4-7 years. ART regimens were not standardized. Most regimens 
consisted of two nucleoside analogues and a protease inhibitor or a non nucleoside reverse 
transcriptase inhibitor. The studies in DRC, Ivory Coast, Jamaica and South Africa were 
carried out in hospital clinics in urban settings. The Kenyan study took place in rural and 
urban clinics. 
 
Impact of ART on TB risk 
All studies reported a protective effect of ART on TB risk. The effect estimates ranged from 
0.12 in South Africa to 0.51 in the DRC. One of the South African studies conducted a 
sensitivity analysis including only culture confirmed TB cases.43 This did not change the 
effect estimate (0.30 compared to 0.25). The median TB risk reduction was 0.22. The 
magnitude of the effect is comparable with data from adults showing a TB risk reduction of 
0.23 due to ART.33 The studies included in this review were heterogenic with regards to 
study population and TB diagnosis. However effect estimates were remarkably similar with 
the exception of one study conducted in the DRC reporting a risk reduction of 0.51. 
Only one study was conducted in infants. The study was the only randomized controlled 
trial and thus is unlikely to be influenced by survival bias as some of the studies in older 
children might have been. Infants were randomly allocated to receive ART immediately or 













INH Preventative Therapy 
 
The available evidence indicates that IPT decreases the risk of TB disease in 
immunosupressed HIV- infected children and ART decreases TB risk in all HIV-infected 
children including infants. No effect for IPT in infants who were put onto ART early in life 
was shown. 
 
The two studies investigating the protective effect of IPT in HIV-infected South African 
children have informed WHO’s newest recommendations for HIV-infected children older 
than one year of age to receive IPT for 6 months irrespective of TB exposure or tuberculin 
skin test (TST).  IPT may be continued for up to 3 years in areas of high TB prevalence. 
Children less than one year of age who have been started on ART for more than 3 months 
and are continuously screened for TB exposure should not receive IPT unless they have a 
documented TB exposure.45  
 
These recommendations depend on well established and functional programs in high 
prevalence HIV and TB settings to regularly, reliably screen for and diagnose HIV and TB in 
infants. However, access to HIV PCR and TB culture may be limited in resource poor 
settings. Furthermore, diagnosis of TB is often sub-optimal and dependent on scoring 
systems which are particularly unreliable in HIV-infected children.46 47  To safely implement 
IPT one needs to be able to reliably exclude TB disease thereby avoiding the emergence of 
drug resistant TB by the inadvertent use of mono-therapy. 
 
Scale up of IPT for HIV-infected children may be challenging from a programmatic point of 
view. Evidence suggests that in HIV- uninfected children IPT is poorly implemented at a 
primary health care level. A recent survey in an urban community in South Africa evaluating 
the current system of IPT delivery showed that only 21% of children eligible for IPT 
received this. There were no standardized IPT management tools in place.48 Another study 
from South Africa reported missed opportunities in 50% of children with TB contacts.21 A 
study done in Malawi showed less than 10% of child TB contacts were screened for TB or 
offered IPT.49 50 This stresses the need for implementing systems or strengthening existing 












Barriers to IPT implementation could possibly be overcome by simplified algorithms for TB 
screening, the creation of a national policy regarding IPT and engagement of affected 
communities.51 
According to current recommendations, HIV-infected infants on ART should not receive 
IPT, with the proviso that they are regularly screened for TB exposure. However, in a high 
TB prevalence context such as South Africa, this is the group with the highest risk. One 
study reported a relative risk of culture confirmed TB of 24.2 in HIV-infected infants.21 
Moreover, regular screening of children for TB exposure and contact tracing of children 
exposed to an adult TB contact is notoriously poorly done within TB programs. Apart from 
trial conditions, vigilance is likely to be poor and tracing of contacts and provision of post 
exposure IPT not widely implemented.  
 
The optimal duration of IPT in children has not yet been established. Studies from 
Botswana and South Africa involving HIV-infected adults suggest that increased benefits 
may be gained with a 36 month regimen as compared to a six month regimen.52 53 This was 
not confirmed in a trial carried out in India.54 
 
In summary, there is an urgent need for more data on IPT in HIV-infected children. 
Increasing numbers of children will be started on ART as access and affordability improves 
and the question of whether IPT provides additional benefits to ART in preventing TB 





WHO now recommends starting ART as soon as possible in infants after a confirmatory 
HIV test at 6 weeks of age, irrespective of CD4 measures.55 Roll out of ART to all HIV-
infected infants presents several challenges. Diagnosis of HIV in infants relies on access to 
HIV PCR, which is lacking in most low income countries. Most importantly well functioning 
PMTCT programs are paramount to early diagnosis of HIV in children. While PMTCT 
programs have been scaled up over the last years gaps in access are still evident. ART 
programs for children are subject to operational problems such as continuous drug supply, 












An important finding is that although ART decreased the incidence of TB, HIV-infected 
children on ART are still at a higher risk of developing TB disease than HIV negative 
immune competent children.59 Therefore other strategies are needed together with ART to 
decrease the risk of TB in these children. No studies have reported on the combined effect 















The evidence suggests that IPT and ART independently decrease TB risk in HIV- infected 
children. The effect of IPT is inconclusive with the two trials showing conflicting results, 
probably as a result of different patient populations. IPT is protective in HIV-infected 
children older than 1 year who are not receiving ART. ART is protective in children of all 
ages but HIV- infected children are still at increased risk of TB disease compared to 
immune competent children. The impact of the combined effect of IPT and ART in HIV-














Table 1: Differences between study population in Zar27 and the P1041 study28 
Study ZAR et al P1041 
Median age in months 25 (9-52) 3.3(3.1 -4) 
CDC – B or C 88% 8% 
Previous TB 16% 0% (exclusion criteria) 
Median CD4 % 20 (14-28) 28 (6-58) 
Received ART 9% 72% 












Table 2. Studies reporting tuberculosis incidence rates during in children antiretroviral therapy 
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Walters et al, 200859 South Africa 290 




Most had severe 
CD4 count 
depletion 






0.12 (AHR) +/- 900 









48.3%  severe 
immune 
depletion 
20.4 10.2 0.51 430 
Kouakoussui et al, 200440 Ivory Coast 270 




8.7% 8.5 1.9 0.22 606 
Martinson et al, 200943 South Africa 1132 
September 1994 
to June 2006 
Retrospective 
cohort 
15% 21.1 6.4 0.3 +/- 900 
Pierre et al 200839 Jamaica 197 




595 (absolute) 1.07 0.14 0.13 6.6 














Violari et al, 200844 South Africa 377 


















1. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden 
and antibiotic resistance of bacteria causing severe community-acquired lower respiratory 
tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 
2000;31(1):170-6. 
2. Jeena PM, Pillay P, Pillay T, Coovadia HM. Impact of HIV-1 co-infection on presentation 
and hospital-related mortality in children with culture proven pulmonary tuberculosis in 
Durban, South Africa. Int J Tuberc Lung Dis 2002;6(8):672-8. 
3. Zar HJ, Hanslo D, Tannenbaum E, Klein M, Argent A, Eley B, et al. Aetiology and 
outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in 
South Africa. Acta Paediatr 2001;90(2):119-25. 
4. Marais BJ, Graham SM, Cotton MF, Beyers N. Diagnostic and management challenges 
for childhood tuberculosis in the era of HIV. J Infect Dis 2007;196 Suppl 1(196):S76-85. 
5. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of 
Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 
1996;157(3):1271-8. 
6. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. 
Lancet Infect Dis 2008;8(8):498-510. 
7. Marais B, Hesseling A, Gie R. The burden of childhood tuberculosis and the accuracy of 
routine surveillance data in a high-burden setting. Int J Tuberc Lung Dis 2006;10:259-63. 
8. Mahomed H, Kibel M, Hawkridge T, Schaaf HS, Hanekom WA, Iloni K, et al. The impact 
of a change in bacille Calmette-Guerin vaccine policy on tuberculosis incidence in children 
in Cape Town, South Africa. Pediatr Infect Dis J 2006;25(12):1167-72. 
9. Harries AD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006;100(5-6):415-31. 
10. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural 
history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-
chemotherapy era. Int J Tuberc Lung Dis 2004;8(4):392-402. 
11. Guidance for national tuberculosis and HIV programmes on the management of 
Tuberculosis in HIV –infected children: Reccomendations for a public health approach. 
Geneva, Switerland: World Health Organization 2010. 
12. Guidelines for the investigation of contacts of persons with infectious tuberculosis. 
Recommendations from the National Tuberculosis Controllers Association and CDC. 
MMWR Recomm Rep 2005;54(RR-15):1-47. 
13. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in 
non-HIV-infected persons. Cochrane Database Syst Rev 2000;2(2):CD001363. 
14. Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis 
1962;86:810-22. 
15. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic 
use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490-510. 
16. Hsu KH. Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of 
the effectiveness in children. Jama 1974;229(5):528-33. 
17. Hsu KH. Thirty years after isoniazid. Its impact on tuberculosis in children and 
adolescents. Jama 1984;251(10):1283-5. 
18. Mount FW, Ferebee SH. Preventive effects of isoniazid in the treatment of primary 
tuberculosis in children. N Engl J Med 1961;265:713-21. 
19. Pillay T, Khan M, Moodley J, Adhikari M, Padayatchi N, Naicker V, et al. The increasing 
burden of tuberculosis in pregnant women, newborns and infants under 6 months of age in 












20. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum 
tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, 
India, 2002-2005. Clin Infect Dis 2007;45(2):241-9. 
21. Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B, et al. High 
incidence of tuberculosis among HIV-infected infants: evidence from a South African 
population-based study highlights the need for improved tuberculosis control strategies. 
Clin Infect Dis 2009;48(1):108-14. 
22. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol 
Rec: Global Advisory Committee on Vaccine Safety, 2007:181-196. 
23. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The 
impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence 
in HIV-infected patients in Rio de Janeiro, Brazil. Aids 2007;21(11):1441-8. 
24. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. 
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South 
Africa: a prospective cohort. Aids 2009;23(5):631-6. 
25. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in 
HIV-infected persons. Cochrane Database Syst Rev;20(1):CD000171. 
26. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis 
and mortality in HIV-infected children. Cochrane Database Syst Rev 2009;21(1):CD006418. 
27. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of 
isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: 
randomised controlled trial. BMJ 2007;334(7585):136-43. 
28. Madhi S, McSherry G, Violari A. Efficacy of Primary Isoniazid (INH) Prophylaxis in 
Reducing Tuberculosis (TB) Free Survival in HIV-infected (HIV+) African Children. 48th 
Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: IDSA / 
ASM, 2008. 
29. Gray D, Nuttall J, Lombard C, Davies MA, Workman L, Apolles P, et al. Low Rates of 
Hepatotoxicity in HIV-infected Children on Anti-retroviral Therapy with and Without 
Isoniazid Prophylaxis. J Trop Pediatr 2009;26:26. 
30. Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. 
Adverse events with isoniazid preventive therapy: experience from a large trial. Aids;24 
Suppl 5(24):S29-36. 
31. le Roux SM, Cotton MF, Golub JE, le Roux DM, Workman L, Zar HJ. Adherence to 
isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing 
two dosing schedules. BMC Med 2009;7(67):67. 
32. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated 
tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009;30(4):685-99, viii. 
33. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals 
and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in 
settings with limited health-care resources. Lancet Infect Dis;10(7):489-98. 
34. Elenga N, Kouakoussui KA, Bonard D, Fassinou P, Anaky MF, Wemin ML, et al. 
Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-
infected children in Abidjan, Cote d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J 
2005;24(12):1077-82. 
35. Tena GN, Young DB, Eley B, Henderson H, Nicol MP, Levin M, et al. Failure to control 
growth of mycobacteria in blood from children infected with human immunodeficiency virus 
and its relationship to T cell function. J Infect Dis 2003;187(10):1544-51. 
36. Kampmann B, Tena-Coki GN, Nicol MP, Levin M, Eley B. Reconstitution of 













37. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune 
responses to Mycobacterium tuberculosis? Implications for tuberculosis control. Aids 
2005;19(11):1113-24. 
38. Global TB database: World Health Organization, 2009. 
39. Pierre RB, Steel-Duncan JC, Evans-Gilbert T, Rodriguez B, Moore J, Palmer P, et al. 
Effectiveness of antiretroviral therapy in treating paediatric HIV/AIDS in Jamaica. West 
Indian Med J 2008;57(3):223-30. 
40. Kouakoussui A, Fassinou P, Anaky MF, Elenga N, Laguide R, Wemin ML, et al. 
Respiratory manifestations in HIV-infected children pre- and post-HAART in Abidjan, the 
Ivory Coast. Paediatr Respir Rev 2004;5(4):311-5. 
41. Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F. Anti-retroviral 
therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 2009;15:15. 
42. Braitstein P, Nyandiko W, Vreeman R, Wools-Kaloustian K, Sang E, Musick B, et al. 
The clinical burden of tuberculosis among human immunodeficiency virus-infected children 
in Western Kenya and the impact of combination antiretroviral treatment. Pediatr Infect Dis 
J 2009;28(7):626-32. 
43. Martinson NA, Moultrie H, van Niekerk R, Barry G, Coovadia A, Cotton M, et al. HAART 
and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective 
cohort. Int J Tuberc Lung Dis 2009;13(7):862-7. 
44. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early 
antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 
2008;359(21):2233-44. 
45. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for 
people living with HIV in resource-constrained settings. Geneva, Switzerland: World Health 
Organization, 2010. 
46. Van Rheenen P. The use of the paediatric tuberculosis score chart in an HIV-endemic 
area. Trop Med Int Health 2002;7(5):435-41. 
47. Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined 
symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics 
2006;118(5):e1350-9. 
48. Van Wyk SS, Hamade H, Hesseling AC, Beyers N, Enarson DA, Mandalakas AM. 
Recording isoniazid preventive therapy delivery to children: operational challenges. Int J 
Tuberc Lung Dis;14(5):650-3. 
49. Nyirenda M, Sinfield R, Haves S, Molyneux EM, Graham SM. Poor attendance at a 
child TB contact clinic in Malawi. Int J Tuberc Lung Dis 2006;10(5):585-7. 
50. Claessens NJ, Gausi FF, Meijnen S, Weismuller MM, Salaniponi FM, Harries AD. 
Screening childhood contacts of patients with smear-positive pulmonary tuberculosis in 
Malawi. Int J Tuberc Lung Dis 2002;6(4):362-4. 
51. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al. Implementation 
of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. 
Aids;24 Suppl 5(24):S57-65. 
52. Samandari TMM, B., Agizew T, Nyirenda S, Tedla Z, T. S. Randomized, placebo-
controlled trial of 6 vs 36 months isoniazid TB preventive therapy for HIV-infected adults in 
Botswana. Conference on Retrovirus and Opportunistic Infections. San Francisco, 2010. 
53. Martison NB, Barnes G, Msandiwa R, Moulton LH, Gray G, McIntyre J. Novel regimesn 
for treating latent TB in HIV-infected adults in South Africa: a randomized clinical trail. 
Conference on Retroviruses and Opportunistic Infections. Montreal, 2009. 
54. Swaminathan S, Menon PA, Perumal V, Santhanakrishnan R, Ramachandran R, 
Chinnaiah P. Efficacy of a 6-month vs a 36-month regimen for prevention in HIV-infected 
persons in Inida: a randomized clinical trial. Conference on Retroviruses and Opportunistic 












55. Antiretroviral therapy for HIV infection in infants and children: Towards universal 
access. Recommendations for a public health approach: 2010 revision. Geneva, 
Switerland: World Health Organization, 2010. 
56. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in 
care in middle-income and low-income countries: current status of knowledge and research 
priorities. Curr Opin HIV AIDS 2010;5(1):70-7. 
57. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to 
HAART: a systematic review of developed and developing nation patient-reported barriers 
and facilitators. PLoS Med 2006;3(11):e438. 
58. Rosen S, Fox MP, Gill CJ, Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral 
therapy programs in sub-Saharan Africa: a systematic review. PLoS Medicine / Public 
Library of Science 2007;4(10):e298. 
59. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical 
presentation and outcome of tuberculosis in human immunodeficiency virus infected 















PART C  
The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis 
(TB) in HIV-infected children in a high TB incidence setting. 
 
Co-Authors  
 K Kranzer2, MF Cotton3, HS Schaaf3 CJ Lombard4, HJ Zar1 
1Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, 
South Africa, 2Clinical Research Unit, Department of Infectious and Tropical Diseases, 
London School of Hygiene and Tropical Medicine, UK, 3Department of Paediatrics and 
Child Health, Stellenbosch University, South Africa, 4Biostatistics Unit, Medical Research 
Council, South Africa 
 
Contribution of the candidate 
The candidate undertook the study concept and supervised and aided in acquisition of 
data, analysis and interpretation of data. She drafted the article and the final version 
incorporating comments from co authors. 
 
Publication Status 












The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis 
(TB) in HIV- infected children in a high TB incidence setting. 
 
LJ Frigati1, K Kranzer2, MF Cotton3, HS Schaaf3,CJ Lombard4, HJ Zar1 
1Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, 
South Africa, 2Clinical Research Unit, Department of Infectious and Tropical Diseases, 
London School of Hygiene and Tropical Medicine, UK, 3Department of Paediatrics and 
Child Health, Stellenbosch University, South Africa, 4Biostatistics Unit, Medical Research 
Council, South Africa 
 
Correspondence: 
Dr LJ Frigati lisafrigati@yahoo.com 
Department of Paediatrics and Child Health,  







Word count: Abstract= 247 Text = 2858 Tables=2 Figure=1 References=27 
Trial registration - Clinical Trials NCT00330304 
Keywords: Isoniazid, highly active antiretroviral therapy, tuberculosis, HIV, child, prevention 
 
What is the key question?  
Does INH prophylaxis (IPT) reduce TB in HIV-infected children on antiretroviral therapy 
(ART)? 
 
What is the bottom line?  
IPT provides additional protection against TB disease in children taking ART 
 
Why read on? 













Background: Tuberculosis (TB) is a major cause of morbidity and mortality among HIV-
infected children. Strategies to prevent TB in children include isoniazid preventive therapy 
(IPT) and antiretroviral therapy (ART). IPT and ART have been reported to reduce TB 
incidence in adults but there are few studies in children.  
Objective: To investigate the combined effect of IPT and ART on TB risk in HIV-infected 
children  
Methods: A cohort analysis was done within a prospective, double-blinded, placebo-
controlled trial of INH compared to placebo in HIV-infected children in Cape Town, South 
Africa, a high TB incidence setting. In May 2004 the placebo arm was terminated and all 
children were switched to INH. ART was not widely available at the start of the study, but 
children were started on ART following the establishment of the national ART program in 
2004. Data were analyzed using Cox proportional hazard regression. 
Results: After adjusting for age, nutritional status and immunodeficiency at enrolment INH 
alone, ART alone and INH combined with ART reduced the risk of TB disease by 0.22 
(95% CI 0.09-0.53), 0.32 (95% CI 0.07-1.55) and 0.11 (95% CI 0.04-0.32) respectively. INH 
reduced the risk of TB disease in children on ART by 0.23 (95% CI 0.05-1.00).  
Conclusions: The finding that IPT may offer additional protection in children on ART has 
significant public health implications, as this offers a possible strategy for reducing TB in 
HIV-infected children. Widespread use of this strategy will however require screening of 
children for active TB disease.  
 















Tuberculosis (TB) is an important cause of morbidity and mortality in children living in high 
TB incidence settings.1 2 The incidence and severity of childhood TB is increased by HIV 
infection. A recent study reported a relative risk for developing culture proven TB in HIV-
infected infants, of 24.2 (95% confidence interval [CI] 17-34) compared to HIV-uninfected 
infants.3 Furthermore, HIV-infected children with TB infection are at risk of more rapid 
progression to disease, more severe disease and increased mortality.4-6 
Bacille Callmette Guerin (BCG) vaccination, isoniazid preventive therapy (IPT) and 
antiretroviral therapy (ART) are possible strategies to prevent TB in HIV–infected children. 
World Health Organization (WHO) guidelines have recently been revised to recommend 
against BCG vaccination in HIV-infected infants due to the high risk of disseminated BCG 
and associated mortality.7  
Limited data suggest that IPT8 or ART9 10 can independently reduce TB incidence and 
mortality in HIV-infected children. We have previously report d that IPT (irrespective of TB 
exposure) reduced the risk of TB in HIV-infected children not on ART by approximately 
50%.8 11 Another South African study found that IPT did not decrease risk of TB in HIV-
infected children under 12 months.12 These studies have informed the recent revised WHO 
guidelines recommending IPT for 6 months for all HIV–infected children above 12 months 
of age.13 
A retrospective study found that ART substantially reduced TB incidence in HIV-infected 
children, with 53 TB cases per 100 patient years prior to use of ART compared to 6.4 on 
ART.9 However, HIV-infected children on ART still have a higher risk of TB than HIV-
uninfected children.9 
Observational studies suggest that INH preventive therapy is protective in adults receiving 
ART.14 15 Several randomized trials investigating the combined effect of IPT and ART are 
underway in adults but data in children are scarce. The objective of this study was to 
investigate the combined effect of IPT and ART on TB risk in HIV-infected children living in 














A cohort study was performed as part of a prospective, double-blinded, placebo-controlled 
trial of INH, given with cotrimoxazole either daily or three times a week in HIV-infected 
children in two centers in Cape Town, South Africa. The study area has one of the highest 
incidence rates of childhood TB globally, 407/100 000 in children less than two years of 
age.16 The study started in January 2003; in May 2004 the placebo arm was terminated on 
the recommendation of the Data Safety and Monitoring Board (DMSB) as interim analyses 
demonstrated significant benefit of INH on mortality, the primary outcome. INH was found 
to reduce mortality by 54% [0.22- 0.95 95% CI].8 Thereafter, all children were placed on 
INH daily or three times a week until December 2007 when INH was discontinued on the 
advice of the DSMB as almost all of the children had started on ART.  
A cohort analysis was performed to investigate the combined effect of INH and ART on TB 
risk in children enrolled in the study from January 2003 through December 2007. 
 
Study population 
The study population comprised HIV-infected children older than 8 weeks attending Red 
Cross Children’s Hospital, University of Cape Town or Tygerberg Children’s Hospital, 
Stellenbosch University. 98% of children were black South African from low socio-economic 
background. Inclusion criteria were a weight greater than 2.5kg, and ability to attend regular 
follow-up visits. Exclusion criteria were current use or need for IPT, prior hypersensitivity to 
sulphur drugs or INH, severe anaemia (haemoglobin < 70 g /l), neutropaenia (absolute 
neutrophil count < 400 cells /ul) and non-reversible renal failure. TB disease at the time of 
enrolment was not an exclusion criterion but children completed TB therapy according to 
national guidelines and thereafter were randomized to INH or placebo. All children were 
classified according to WHO clinical staging (stage 1 to 4).  
 
Follow-up 
The study team evaluated the children every four weeks for the first six months, every six 
weeks for the second six months and thereafter every two to three months depending on 
medical and social circumstances. Clinical and historical data were collected at each visit. A 
tuberculin skin test (TST, 2 TU RT23, Staten Serum Institute, Copenhagen, Denmark), and 
chest radiograph were done at 6 monthly intervals. A child exposed to a TB source (case), 












study period was investigated for TB infection and disease. For pulmonary TB this included 
a TST, a chest radiograph and two induced sputum specimens for acid fast staining and 
Mycobacterium tuberculosis (M. tuberculosis) culture. Additional specimens were submitted 
as clinically indicated. Children exposed to a household TB case were given IPT according 




Enrolment began in January 2003. Children enrolled before May 2004 were randomly 
allocated to receive INH (10 mg/kg) or placebo. All children receiving placebo were 
switched to INH in May 2004. All children enrolled thereafter received INH. INH was 
stopped in all children in December 2007. 
 
ART 
ART was not widely available at the start of the study but was obtained for some children 
through participation in pharmaceutical trials or charitable donations. Children were started 
on a double NRTI backbone (Zidovudine, Lamivudine, Stavudine) combined with either a 
NNRTI (Efavirenz or Nevirapine) or a protease inhibitor (Ritonavir/Lopinovir or Ritonavir 
only). Standard guidelines for ART in children were developed after the establishment of 
the national ART program in 2004. Thereafter increasing numbers of children initiated 
therapy according to medical and social criteria described in the national guidelines.  
 
Diagnosis of TB 
Cases of TB were classified as definite or probable according to clinical, radiological and 
microbiological findings as follows: (1) Definite TB: culture positive for M tuberculosis on a 
sputum or other sample; (2) Probable TB: chest radiograph suggestive of TB 
(lymphadenopathy, miliary pattern, pleural effusion, bronchial compression or parenchymal 
infiltrate) plus at least one of the following: a positive TST, a history of a close contact with 
an adult with TB, loss of weight or failure to gain weight within the previous 3 months, or a 
positive smear microscopy for acid fast bacilli on sputum. Chest radiographs were reported 
by a single radiologist, blinded to the diagnosis of TB, according to a standardized format. 
Probable cases were reviewed by an independent experienced pediatrician blinded as to 














A prospective cohort study was performed to investigate the effect of INH and ART on TB 
incidence. Individuals were censored at death, date of TB diagnosis, loss to follow-up or on 
the 31 December 2007. Individuals could contribute time to four groups: time on placebo 
only, time on INH only, time on ART only, time on ART and INH (figure 1).  
 
Confounding variables 
The degree of immunodeficiency at enrolment was grouped according to WHO CD4 
classification.17 Categories 1 and 2 (insignificant or mild) and categories 3 and 4 (moderate 
or severe) were grouped together. WHO clinical staging at enrolment was grouped as stage 
1 and 2 or stage 3 and 4 combined. The z-scores for nutrition were grouped as >-2 (normal 
or mild) or <-2 (moderate or severe). 
 
Statistical analysis 
All analysis was conducted using Stata (version 10.1, College Station, Texas). Descriptive 
statistics of the baseline data and follow-up data of the cohort were calculated as medians, 
25th and 75th percentiles and frequencies. 
Cox proportional hazards regression was performed using time since randomization as the 
time scale. Records were split for time dependent exposure and age at follow-up. The 
analysis was performed taking dependency of records into account. Univariable analyses 
were conducted using immunodeficiency, anthropometric z-scores and age at enrolment 
(grouped as 0-2 years, 2-5 years and more than 5 years), gender, prior TB, daily or three 
times per week regimens for INH /cotrimoxazole, placebo, INH, ART and INH and ART. 
Hazard proportionality was assessed by analysis of scaled Schoenfeld residuals. 
Age at follow-up and immunodeficiency at enrolment were included a priori in the 
multivariable model. Possible other confounders including WHO clinical staging and 
nutritional status at enrolment and prior TB, gender were assessed with regards to their 















The study was approved by the ethics committees of the Faculty of Health Sciences, 
University of Cape Town and of Stellenbosch University. Written informed consent was 














Baseline characteristics  
Two hundred and ninety eight children (median age 2.09 years) were enrolled. At 
enrolment 117 children were randomly assigned to receive placebo and 181 to INH (figure 
1). Of 117 children assigned to receive placebo, 78 were switched to INH after May 2004 
while 39 were censored (lost to follow-up, died or diagnosed with TB) before May 2004. In 
summary there were 3 INH groups: (I) children who received INH throughout follow-up 
(n=181), (II) children who initially received placebo and were then switched to INH (n=78) 
and (III) children who only received placebo during follow-up (n=39). Overall, 39 (13%) 
children were on ART at enrolment, while 135 (45%) started ART during the study. The 
total time of follow-up was 495.65 person years: 42.02 person years on placebo/no ART, 
12.67 person years on placebo/ART, 207.73 person years on INH/no ART and 233.23 
person years on INH/ART. A total number of 37 children died: 15 on placebo, 2 on ART, 14 
died on INH and 6 on INH plus ART. 
At enrolment, most children were mildly undernourished with a median height for age z-
score of -1.91 and weight for age z-score of -1.34 (table 1). The majority had severe clinical 
disease, with 82% in WHO stage 3 or 4. Most (83%) had advanced or severe 
immunodeficiency (table 1). Forty-one (13%) children were diagnosed with TB at 
enrolment. The median follow-up time was 21.7 months with a median time on INH of 20.3 
months and median time on ART of 17.9 months. During this period, 39 cases of TB were 
diagnosed (19 definite and 20 probable). INH was well tolerated with excellent adherence 
using pill count and adherence counseling. There was no increased risk of elevated liver 
enzymes, jaundice or fulminant liver failure in children taking ART and IPT.18 19 
 
Effect of INH, ART and INH plus ART 
Univariable Cox regression analysis showed no association between gender, weight for 
age z-score, weight for height z-score and history of TB disease (table 2). More advanced 
clinical disease and immunodeficiency at enrolment increased the risk of TB disease, as did 
more severe stunting. ART alone and INH alone reduced the risk of TB disease by 0.35 
and 0.24 respectively. INH and ART combined reduced TB risk by 0.14 (95% confidence 
interval (CI) 0.05-0.35) compared to placebo. 
Multivariable analysis showed that, after adjusting for age at follow-up, nutritional status 












0.09-0.53). ART alone reduced TB risk by 0.32 (95% CI 0.07-1.55) compared to placebo. 
The combination of INH and ART reduced the risk of TB by 0.11 (95% CI 0.04-0.32) (table 
2). Restricting the analysis to children receiving ART revealed a TB risk reduction of 0.23 














This is the first study to suggest that IPT reduces TB risk in children receiving ART. Overall, 
there was a 0.11 risk reduction of TB disease in children receiving both INH and ART 
compared with children receiving neither. While, INH and ART independently reduced TB 
risk by 0.22 and 0.32 respectively, the combination of INH and ART reduced the risk by 
0.11. In children on ART INH reduced the risk of TB disease by 0.23. 
The protective effect of ART on TB risk has been reported in children.9 10  ART reduces 
susceptibility to M tuberculosis by improving immunity, and enabling more effective 
containment of TB infection.20 21 The benefit of IPT in preventing TB disease in TST positive 
HIV-infected adults has clearly been shown.22 Studies in HIV-infected adults found a TB risk 
reduction of 76% in individuals receiving IPT and ART compared with those receiving 
neither.14 15 A possible explanation for this added benefit is the effect of INH in treating 
latent infection and preventing progression to disease. In young children, TB disease 
usually represents progression of primary infection rather than reactivation of latent 
infection, therefore the mechanism of the additional effect of IPT in children receiving ART 
as occurred in our study may be through containment of primary infection. 
Diagnosis of TB infection or pulmonary disease is challenging in HIV-infected children due 
to anergy and difficulty in obtaining a microbi logical diagnosis. A concern for implementing 
IPT is inadvertent use in pulmonary TB, thereby promoting drug resistance. In this study all 
children were carefully screened for TB at enrolment, including repeated induced sputum 
samples. As evidence of the effectiveness of screening, 41 (13.8%) children were 
diagnosed with TB at enrolment and commenced on TB therapy. This high proportion of 
newly diagnosed TB through active case finding highlights the importance of appropriate 
screening tools before the rolling out of IPT. 
Intensive surveillance for TB infection and disease was done in the study through close 
clinical, radiological, immunological and microbiological follow-up. We did not identify TB in 
any of the children who died. Three children developed INH-resistant TB although one had 
contact with a multi drug resistant case. A study including children from this cohort reported 
3.4% of grade 3 and 4 elevation in ALT in children on ART and INH. All children were 
asymptomatic and no children developed clinical jaundice or fulminant hepatic failure.18 
Age, nutritional status and CD4 count at enrolment were confounders and as such included 
in the final multivariable model. The association between age and TB did not reach 












of developing severe TB disease is highest in infants; HIV-infected children are at risk of M 
tuberculosis disease at all ages. The level of immunodeficiency was not significantly 
associated with TB in this cohort. Most children had moderate or severe 
immunosuppression at enrolment but CD4 percentage is unlikely to correlate with CD4 
percentage during follow up, as use of ART during the study would affect CD4 measures.  
The strengths of this study include blinding to eliminate diagnostic bias and follow-up of 
long duration that ensured reliable outcome ascertainment. A limitation of this study was 
that ART was not randomly allocated. The early termination of the placebo arm reduced the 
follow-up time that this group could contribute, and may have reduced the power but 
continuation of the placebo arm was not ethically possible, given the effect of INH on 
mortality and the recommendation by the DSMB.8  
Survival bias might have potentially influenced the results. When the data were analyzed 
using a nested matched case control design, where 1 case was matched on age and 
follow-up time to 1-4 controls results were similar to the cohort study. Changes in TB 
incidence for example, a decrease in TB incidence, could also have biased the estimates. 
National and local TB incidence was increasing during the study period. 23 Finally, the 
protective effect of ART is not immediate and may be seen many months after initiating 
treatment. The study was done over 5 years with a median follow-up time of 20 months, 
thus enabling sufficient time to investigate the effect of ART.  
Initiation of ART may unmask TB, which could dilute the possible protective effect of ART 
on TB risk. Due to the young age group, latent TB infection is not common and thus 
immune reconstitution inflammatory syndrome (IRIS) due to unmasking would be unlikely. 
In addition, no cases of BCG IRIS were documented. Currently IPT is not recommended for 
HIV-infected children less than 12 months (without history of TB exposure).13 If IPT, ART 
and Cotrimoxazole prophylaxis were to be initiated as a ‘package of care’ at two to three 
months of age, then the need to screen for active TB would be greatly reduced and IRIS 
would be less likely.  
The finding that IPT is protective in children on ART has significant public health 
implications, as this offers a possible strategy for reducing TB in HIV-infected children. The 
effect of IPT is obviously dependant on the level of TB exposure and the results of this 
study should be interpreted in a context of a high TB prevalence setting. They may not 
apply to a low TB prevalence setting. Widespread use of this strategy will however require 
screening of children for active TB disease. The optimal duration of IPT has not been 














This is the first study to suggest a protective effect of INH in children on ART. The 
expansion of IPT for HIV-infected children has a number of health system challenges, 
including the ability to detect and exclude active TB disease before commencing IPT. 
Nevertheless, IPT may safely reduce TB incidence in HIV-infected children on ART. Further 
studies are needed to determine the optimal duration that IPT can be safely continued in 
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Table 1: Baseline characteristics of children enrolled (N=298)  
 
Variables N (%) or Median (IQR) 
Age (years)  2.09 (1.03, 4.11) 
Gender 
Female 135 (45.3%) 
Male 163 (54.7%) 
WHO clinical stage 
at enrolment 
Stage 1 12 (4.1%) 
Stage 2 41 (14.1%) 
Stage 3 177 (60.8%) 
Stage 4 61 (21.0%) 
WHO CD4 depletion 
at enrolment 
Category 1 = not significant 30 (10.1%) 
Category 2 =mild 20 (6.7%) 
Category 3 = advanced 49 (16.4) 
Category 4 = severe 199 (66.8%) 
Anthropometry at 
enrolment 
Height for age Z- score -1.91 (-2.87, -0.94) 
Weight for age Z-score -1.34 (-2.41, -0.43) 
Weight for Height Z-score -0.17 (-1.07, 0.72) 
History of TB 
disease 
None 236 (79.2%) 
Prior to enrolment 21 (7.0%) 
TB treatment at enrolment 41 (13.8%) 
Cotrimoxazole/INH 
Daily 145 (48.7%) 
3 times a week 153 (51.3%) 
INH 
Placebo throughout the study 39 (13.1%) 
Initial Placebo, switched to INH 78 (26.2%) 
INH throughout the study 181 (60.7%) 
ART 
At enrolment 39 (13.1%) 
Started during the study 135 (45.3%) 
No ART 124 (41.6%) 
Time on ART (months) N=174 17.92 (10.6; 26.2) 
Time on INH (months) N=259 20.03 (14.5; 27.8) 












   
Table 2: Effect of INH, ART and INH combined with ART on TB risk 
Variables 
Univariable Multivariable 
HR (95% CI) P HR (95% CI) P 
Gender 
Male 1    
Female 1.01 (0.54; 1.90) 0.970   
Age at follow-up 
0-2 1    
2-5 0.78 (0.37; 1.66) 0.511 0.74 (0.33; 1.55) 0.445 
>5 0.68 (0.29; 1.60) 0.384 0.79 (0.33; 1.91) 0.603 
WHO clinical stage at enrolment 
1 or 2 1    
3 or 4 1.52 (0.60; 3.86) 0.390   
Immunodeficiency at enrolment 
Mild 1    
Advanced/severe 2.44 (0.73; 8.09) 0.144 2.74 (0.78; 9.68) 0.117 
Z-score (height for age) at enrolment 
Mild 1    
Moderate/severe 1.80 (0.96; 3.39) 0.068 1.84 (0.99; 3.42) 0.055 
Z-score (weight for age) at enrolment 
Mild 1    
Moderate/severe 1.00 (0.51; 1.96) 0.098   
Z-score (weight for height) at enrolment 
Mild 1    
Moderate/severe 1.20 (0.40; 3.57) 0.760   
History of TB disease 
No 1    
Yes 0.83 (0.38; 1.80) 0.625   
Cotrimoxazole/INH 
Daily 1    
3 times a week 0.89 (0.48; 1.67) 0.714   
Placebo 1    
ART 0.35 (0.07-1.63) 0.179 0.32 (0.07; 1.55) 0.157 
INH 0.24 (0.11-0.55) 0.001 0.22 (0.09; 0.53) 0.001 












117  receiving placebo  181 receiving INH  
39 receiving placebo throughout 
the follow-up
78 switched to INH during 
the follow-up
28 on ART 
at enrolment
9 on ART at 
enrolment
2 on ART at 
enrolment
83 on ART 
during follow-up




24 no ART 
during follow-up
7 on ART during 
follow-up
30 no ART 
during follow-up
1 TB case 1 TB cases 14 TB cases 3 TB cases4 TB cases 2 TB cases0 TB cases 13 TB cases 1 TB case
Follow-up time: Placebo, no ART: 42.02 person years
Placebo and  ART: 12.67 person years
INH, no ART: 207.73 person years
INH and  ART: 233.23 person years
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PATIENT INFORMATION AND CONSENT FORM 
May 23rd, 2003 
Strategies for prevention of opportunistic infections in HIV-infected South 
African children: Comparison of 2 trimethoprim-sulphamethoxazole 
(cotrimoxazole) prophylaxis regimens with and without concomitant isoniazid 
- impact on morbidity, mortality, bacterial resistance and incidence of 
tuberculosis. 
You and your child are requested to participate in a medical research study 
that is being done at Red Cross and Tygerberg Children 's hospitals. The 
Department of Paediatrics and Child Health of the Universities of Cape Town 
and Stell en bosch are conducting this study. The following information will 
describe the study and your child 's role as a participant. Please read this 
carefully and feel free to ask any questions. The study will be conducted 
according to the Declaration of Helsinki and to MRC and ICH (international 
cornmittee of harmonization) gu idelines. 
Background 
Your child is at risk for developing a chest infection caused by a germ called 
Pneumocystis carini;. This infection may cause a severe chest infection 
(pneumonia). To prevent this, a medicine called cotrimoxazole (or Cozole / 
Bactrim) should be taken by your child e ither 3 times a week or everyday. 
Your child is also at risk for getting tuberculosis (TB) because this is so 
common in the Cape Town area and because your child is unable to fight off 
infections very well because of hislher HIV disease. To prevent TB, a 
medicine called isoniazid (INH) may be given . 
Purpose of the study ""' 
The aims of this study are to 
(1) Compare how effective giving cotri]noxazole 3 times a week is with 
giving it everyday for preventing chest and other infections. 
(2) Investigate whether giving INH either 3 times a week or everyday can 
prevent TB. 
Procedures in the study 
Your child will be given cotrimoxazole to take e ither 3 times a week or 
everyday. Your child will also be given INH as a tablet or a pill that looks like 
the INH tablet but does not contain INH (placebo) to take either 3 times a 
week or everyday. Your child will be seen every month at the Infectious 
Diseases cl inic to check how hel she is doing . At the first visit to the clinic, a 
blood test will be done to measure your child 's ability to fight infection 
(immune status) and a blood specimen will be stored to measure the amount 
of HIV virus in your child. A swab from the nose will also be taken and sent to 
the laboratory where tests will be done to identify the germs living in hislher 
nose . A nose swab will be done every 6 months on you child to see whether 












Appendix 2:Data capture form for each study visit 
 
r--_____ ,-----__ --,---__ -,-___ ,-------.!T'-'M~P-SMX/INH St:udy 
I Study No: 
Dat:e Completed: d ! en , 
Fotlovv-up visit ( m o nths ) i 3 1 6 9 
Surname: 
Date of birth: 
Hospital/C l ini c 
Address. i f ch a n ged: 
Change in car-e; £ : ive r 
Tel nurn ber-(s i 
Another cont3C : "C) 






Runn y ''Ies-:=:; 
\Nheeze 
Poor fe eC::l~~g 
Other: S ;'::'E<:::-
FoIIO\N Up Visits 
By VVhorn: i 
12 1 5 21 24 ; 27 30 
! Name: ~ 
FN 
If y es . n arTlB : 
Site RXH I iSH 
Other: 
y 
























r-:::-:--:--::--:---..,.--__ .-__ --,_--'T'--Nl=-T~P_-S=:..:;MXII N H Sl:udy 
Study No: \ I I Site RXH \ : TBH 
·TS Information 
INH \ Placebo 
Section"": TB oroohyta:x.is cornoleted prl or't.o # (as on En~hne"t 'f'cnTn' 
D a te COrT'\p\et.ed : _____________ _ BY'Nhorn : 
Course 2: 












Appendix 4 : letter of approval of protocol  
Dear Dr Lisa Jane Frigati 
Candidature Approval  ( FRGLIS001 )  
Degree  
MMed in Paediatrics  
 Title 
 The impact of isoniazid prophylaxis and antiretroviral therapy on tuberculosis (TB) 









 I am pleased to advise that the Chair of the Dissertations Committee has approved your 
candidature for the above degree on behalf of the Committee. Formal approval was 
obtained by publication in the Dean’s Circular, Med06/2010. 
Kind Regards 
 Nomkitha Nyamende(Ms) 
Postgraduate Admin 
Faculty of Health Sciences 
University of Cape Town 
Medical School 
Tel: 021 406 6751 












Appendix 5: Ethics Approval
08 April 2002 
REC REF: 057/2002 
Dr. H. Zar 
Paediatrics 
Dear Dr. Zar 
E48- Old Main Building, Groom _wr H"'I'Ital, 
ObseMItory, 7925 
Queries: XoIife Fula 
Tel: (021) 4IlfHl492 Fax: 4OEHl411 
Ewmail: Xfula@cunaucla-c.za 
Thank you for submitting your study to the Research Ethics Committee for 
review, 
It is a pleasure to inform you that the Committee has formally approved your 
study however the Investigator/IS must inform patients and family members 
that antlretrovlral therapy Is available either in trials or can be purchased 
privately at thair own expense, 
Attached is a copy of members who attended the meeting. 
Please quote the above Ree, reference number in all co..".,.pondence 
YOUrZ1~'~( 
AlPROF, CR,SWANEPOEL 
CHAIRPERSON 
Signature removed
